Aim: To compare effectiveness of calcium infusion (CI) versus oral cabergoline (OC) in lowering the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high risk women undergoing in vitro-fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. Patients and methods: This trial was conducted at Benha University Hospital and Hawaa specialized infertility center, including 230 women undergoing ICSI, 115 women received intravenous Calcium gluconate starting at ovum pick up (OPU) day and 115 women received OC 0.5 mg starting at the day of OPU outcomes were the overall incidence of OHSS as well as its type and severity, in addition to others pregnancy outcomes data. Results: The occurrence of overall OHSS was significantly lower in calcium infusion group (CIG) than in oral cabergoline group (OCG) [16/115 (13.9%) in CIG versus 32/115 (27.8%)] in OCG with difference in proportion percentage point (D pp) = À13.9% , at 95%CI of À3.38% to À24.10% (P = 0.009) and absolute risk reduction (ARR) in overall OHSS incidence = 13.9% at 95%CI of 3.38-24.10 and relative risk (RR) = 0.5 at 95% CI of 0.29-0.85 (p = 0.012) and relative risk reduction (RRR) = 50% and number need to treatment (NNT) (Benefit) = 7.18 at 95% CI of 4.12 (Benefit) to 28.05 (Benefit)]. Also the incidence of Moderate OHSS was significantly lower in CIG than OCG [2/115 (1.7 %) vs 10/115 (8.6%), p = 0.01] as well as RR of severe OHSS with CI to OC = 0.25 at 95%CI of 0.02-2.20 and RRR of severe OHSS with CI to OC was 75% as it occurred in 4 cases (3.4%) in OCG versus one case (0.8%) in CIG, where this reduction is of great clinical significant despite it does not reach statistical significance (P = 0.17), at NNT (Benefit) = 38.33 at 95% CI of 87.292 (Harm) to 1 to 15.716 (Benefit) .Other pregnancy outcomes didn't show any statistically significant differences. Conclusion: Calcium infusion is more effective than oral cabergoline intake from OPU day in the reduction of OHSS overall incidence as well as its severity with comparable pregnancy outcomes.
Introduction
Ovarian hyperstimulation syndrome (OHSS) is the most potentially iatrogenic dangerous sequel, with significant high morbidity and mortality, of controlled ovarian hyperstimulation (COH) [1] . OHSS incidence ranges from 33% in mild cases, to 3-6% in moderate cases and to 0.5-5% in severe cases [2, 19] . Clinically, OHSS presented with symptoms and signs related to increased permeability with subsequent third space fluid collection, ascites, abdominal discomfort and enlarged ovaries [2] . OHSS could present within nine days of human chorionic gonadotrophin (HCG) (early onset OHSS) or after ten days (Late onset OHSS) where the trophoblastic HCG is the trigger [3] .
OHSS is a sequel to HCG action on stimulated ovaries where a numerous proinflammatory mediators as the vascular endothelial growth factor (VEGF), Angiotensin II (AGII), interleukin-6 (IL-6), insulin-like growth factor (IGF-I), epidermal growth factor (EGF), transforming growth factor (TGF) a and b, basic fibroblast growth factor (BFGF), platelet-derived growth factor (PDGF) and interleukin 1b (IL-1b) were produced. These mediators directly or indirectly increase capillary permeability leading to fluid leakage into third space from the vascular compartment with third space fluid accumulation [3] .
Several preventive modalities have been used targeting these mediators to lower the incidence of moderate and severe OHSS including, cycle cancellation [4] , coasting [5] ,embryos cryopreser-vation [6] intravenous fluids infusion as albumin [7] , hydroxyethyl starch [8] , calcium infusion [9] , replacing FSH with low-dose HCG [10] , replacing HCG triggering with GnRH agonist in antagonist protocol [10] and dopamine agonist as cabergoline [11, 12] . Unfortunately, none of this employed treatment modalities were completely preventing OHSS after HCG administration in COH in context of IVF/ICSI cycles.
Clinical trials have been assessed clinical usefulness of both cabergoline [11, 12] and calcium infusion [9, 13] and both found to be effective agonist placebo. Also, recent trials assessed cabergoline versus albumin IV [14, 17] . Coasting [15] , however only one reported quasi-randomized trial [18] up till now after searching medical databases like Medline, Embase was found to compare calcium infusion versus oral cabergoline in OHSS prevention.
This study aimed to compare the effectiveness of oral cabergoline and calcium infusion to prevent OHSS in in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles in women at high risks for development of OHSS.
Patients and methods
This prospective, randomized, parallel group, concealed allocation, open labeled, superiority trial was conducted at two IVF centers (Benha IVF center, obstetrics and Gynecology Department of Benha University Hospital, Al Qalubia, Egypt and Hawaa Fertility center, Benha, Egypt) from October 2014 to April 2017. The study protocol was approved by Benha Faculty of Medicine ethics committee and informed written consents were taken from participants in this trial.
All women scheduled for ICSI and at high risk for developing OHSS between October 2014 and April 2017 were asked to participate after couples receiving written and verbal information about the study. The risk of developing OHSS was defined as to be with one of the following criteria: prior episodes of OHSS, polycystic ovaries (i.e., >24 antral follicles present on baseline ultrasound), Large number of small follicles (8-12 mm) seen on transvaginal ultrasound in earlier clinical observation, high serum estradiol (SE 2 ) at hCG trigger (E 2 ! 3000 pg/ml or rapidly rising SE 2 ) or more than 20 retrieved oocytes. All participant women underwent a complete evaluation including clinical history, physical examination, transvaginal ultrasound evaluation, hormonal profile as well as preinclusion cardiologist assessment to women at risk of a possible toxic effect of calcium IV infusions like women on digitalis and those with arrhythmia. The women were excluded from the study if they had other endocrinopathies as hyperprolactinemia, diabetes mellitus or congenital adrenal hyperplasia. Women with systemic diseases like hypertension, bronchial asthma or bleeding disorders were also excluded.
Women were recruited sequentially and assigned to oral cabergoline or calcium infusion at random in 1:1 ratio. The trial statistician created a different sized blocked randomized treatment allocation schedule by using a computer random number generator. The treatment allocation schedule was stored by the infertility consultant (M.A.E), and the point of randomization occurred when women were asked to enter, for ovum pick -up (OPU). After randomization blinding of either patients or staff who followed up patients isn't possible due to nature of study.
In calcium infusion group (CIG) 10 ml of calcium gluconate 10%, in 200 ml 0.9% saline solution were given intravenously on the day of OPU and day 1, 2 and 3 after OPU over 30 min [9, 13, 16] while in oral cabergoline group (OCG) one tablet (0.5 mg)/day taken orally for 7 days stating at day of OPU [17] (Carbergamon 0.5 mg, AMON pharmaceutical CO. SAE, El Obour City, Cairo, Egypt).
All women included were undergoing ICSI cycles through the long protocol, in which the women begin the treatment cycle with the use of combined oral contraceptive pills on day 4 of preceding cycle, down-regulation begins in the mid-luteal phase on day 20 of the cycle with the use of daily subcutaneous injections of GnRH agonist triptorelin (0.1 mg Decapeptyl; Ferring, Germany). Ovarian stimulation started when the patient was down-regulated, as evidenced by endometrial thickness <5 mm and SE2 levels <50 pg/ mL, on day 2 or 3 of her menstrual cycle by daily intramuscular HMG injection (Merional; IBSA, Switzerland). The beginning dose of 150-300 IU was used according to the women's age, antral follicle count, basal FSH level, and previous ovarian response. Usually, the first follow up ultrasound and SE 2 were done on the 5th day of stimulation. Monitoring of follicular growth was done with serial transvaginal ultrasound (TVs) and SE 2 measurements, and the gonadotropin dose was adjusted according to follicular response. Ovulation triggering was by using of 10,000 IU hCG (Choriomon; IBSA, Switzerland) after ultrasound evidence of follicle maturity when at least three follicles showed a size of > or =18 mm.
OPU was 36 h after hCG administration, with the assistance of TVS. Embryos were cultured on a sequentially available commercial culture media system. Assessment of fertilization was done 16-18 h after injection. Cleavage-stage embryos were selected based on the morphologic criteria, and transferred by the Labotect Embryo Catheter (Labor-Technik) under direct transabdominal ultrasound (TAS) guidance. Vaginal progesterone suppositories (400 mg prontogest; IBSA; Macryl; Egypt) were used for luteal support.
Clinical and ultrasound examinations were done on the day of embryo transfer, then weekly to detect the occurrence of OHSS. All patients were instructed to contact a member of infertility unit where OPU was performed if they experienced difficulty in breathing, recurrent vomiting, decreased urine volume, dizziness on standing, abdominal pain, enlargement of the abdomen and rapid weight gain and were evaluated as needed. Patients were monitored on an outpatient basis via phone contact and visits until menstruation occurred or until fetal heart activity was detected in pregnant patients.
According to Humaidan et al. [25] OHSS was diagnosed and classified. Mild OHSS was diagnosed in the presence of pelvic discomfort, abdominal distension, ascites in the pouch of Douglas, and enlarged ovaries. Moderate OHSS was coined in the presence of pelvic pain, abdominal distension, ascites in the pouch of Douglas and pelvis, enlarged ovaries, and abnormal hematologic profiles (hematocrit >45%). Severe OHSS was diagnosed in presence both of the following objective (fluid in the pouch of Douglas, fluid around the uterus, fluid around intestinal loops, hematocrit >45%, white blood cells >15,000/mL, and low urine output [<600 ml/24 h]) and subjective (pelvic discomfort, abdominal distension, breathing difficulty, ovarian enlargement, and pregnancy occurrence) criteria. According to Carizza et al., OHSS was defined as ''late, ''if with an onset !10 days after OPU and OHSS with earlier onset as early" OHSS [33] . Mild and moderate cases were managed symptomatic, while severe OHSS cases were admitted at Benha university hospital high-risk unit of obstetrics and gynecology department.
Chemical pregnancy was diagnosed when BHCC ! 5 m IU/mL after day 14 of embryo transfer and no gestational sac could be detected in follow up visits. Clinical pregnancy was diagnosed when a gestational sac with fetal heart activity was seen on TVs. The implantation rate was the number of gestational sacs divided by the number of embryos transferred.
The primary outcome measure was the overall OHSS rate. Secondary outcomes were its type mild, moderate, and severe OHSS as well as early and late onset OHSS, fertilization rate, implantation rate, chemical pregnancy, clinical pregnancy, ongoing pregnancy, early miscarriage, live birth rate.
A sample size of 115 women per group was calculated, with two sited 5% significance (type I (a) error = 0.05), and efficacy (power) of 85% (type II (B) error = 0.15) and anticipated dropout rate of 15%, after performing internal pilot study on 40 women in each group and found the incidence of total OHSS in cabergoline group (9/40,22.5%) while in calcium infusion group (3/40,7.5%).
Statistical analysis was according to intention to treat analysis and was done by free trial MedCalc easy to use statistical software for window desktop (www.Medcalc.org) 2017 MedCalc, software, bvba [34] . Continuous variables are presented in terms of means and stander deviations, while categorical variables are presented in terms of numbers and percents as appropriate. Chi-square test was used to compare categorical variables as the incidence of overall, early, late, mild, moderate and severe OHSS as well as pregnancy rates. Independent sample Student's t-test was used to compare continuous variables as baseline demographic and clinical criteria as age, hormonal profiles, infertility causes, amount of used HMG, level of SE2 on the day of HCG administration as well as fertilization and implementation rates, as our data were normally distributed. P values and mean or proportion percentage difference with 95% confidence interval (CI) were used to determine significance, P < 0.05 was considered statistically significant.
Results
In the present study, 380 ICSI candidate women were evaluated for eligibility, 230 women were at high risk for development of OHSS without any exclusion criteria and randomized to either receiving calcium infusion or oral cabergoline, 115 in each group. All women randomized were received the allocated treatment as randomized and all these 230 women were included in the primary analysis (Fig. 1) . Table 1 shows participants demographic and clinical-laboratory criteria and shows that there was no significant statistical difference between both groups. Table 2 shows that there was no significant difference between both study arms regarding ovarian stimulation length in days (P = 0.1), total amount of HMG (P = 0.1), peak of E2 on HCG day (P = 0.45) as well as fertilization rate, implantation rate, chemical pregnancy, clinical pregnancy, early miscarriage rate, ongoing pregnancy and live both rate. 3.38-24.10% (P = 0.009) and absolute risk reduction (ARR) of overall OHSS in CIG over OCG = 13.9% at 95% CI of 3.38-24.10% and relative risk (RR) = 0.5 at 95% of CI of 6.29-0.85 (P = 0.01) and relative risk reduction (RRR) = 50% and number need to treatment (NNT) (benefit) = 7.18 at 95% CI of 4.12 (benefit) to 28.05 (benefit)] as well as frequency of moderate OHSS [10/115 (8.6%) in OCG versus 2/115 (1.7%) in CIG], DPP = 6.9% at 95% CI of 10.62-13.76% (P = 0.01), ARR of moderate OHSS in CTG over OCG = 6.9%, While RR = 0.2% at 95% CI of 0.04-0.89% and RRR = 80% and NNT (benefit) = 14.37 at 95% CI of 7.91 (Benefit) to 78.16 (benefit)], while they were no statistically significant difference in incidence of Mild OHSS (P =). The occurrence of severe OHSS was in 4 patients (3.4%) in OCG while in 1 patient (0.8) in CIG, despite that reduction of severe morbidity of COH was of great clinical importance, the rate of occurrence of severe OHSS was not found to be statistically significant [DPP = À2.6% at 95% CI of À1.94-7.87% (P = 0.17)] and ARR of severe OHSS in CIG over OCG = 2.6%, while RR = 0.25 at 95% CI of 0.02-2.20 (P = 0.21) and RRR = 75% and NNT (Benefit) = 38.33 at 95% of 87.29 (Harm) to / to 15.71 (benefit)] . All the four women with severe OHSS from both study arms were hospitalized. Two women in OCG required ascetic tap due to severe ascites and breathing difficulties, While the other two women did not need abdominal paracentesis. All four women were improved, and all four women were discharged once asymptomatic. The participants with mild and moderate OHSS from both study arm were followed up on an outpatient basis until they became asymptomatic.
No apparent complication was recorded in both groups as result of oral intake of cabergoline and intravenous calcium infusion such as hypotension, nausea, vomiting, bradycardia, flushing, tingling sensation, chalky taste, gastric upset. Also, there was no complication from ascetic tap procedures.
Discussion
Severe forms of OHSS may complicate up to 0.5-5% of IVF/ICSI cycles and these may be associated with severe morbidity and even mortality if not timely and efficiently managed [19] . Despite the tried different preventive measures, complete prevention of OHSS isn't achieved, but this measures succeeded to reduce the severity of OHSS which is the cause of maximum concern [20] .
This trial demonstrated that the use of IV calcium infusion is superior to oral cabergoline in reduction of overall incidence, moderate as well as severe OHSS development in high-risk women undergoing IVF/ICSI treatment utilizing long against protocol with timely HCG trigger which is still preferred protocol for IVF/ICSI treatment up till now [11, 21, 22, 23, 24] . As antagonist protocol protective effect for OHSS is needed to be evaluated in well powered randomized trial [22] , and GNRH against usage for ovulation triggering was less effective than HCG triggering in terms of ongoing pregnancy rate and live birth rate [21] as well as recent study that surveys 359 centers in 71 countries found that most used triggering drug in antagonist protocol were HCG [23] . Also, the recent review on usage agonist as a trigger for ovulation instead of HCG recommended that issue still need more research [24] . This trial found that overall incidence of OHSS is statistically significant high in OCG than CIG (27.8% vs 13.9%, P = 0.003). The most common type in both groups was mild which isn't significantly different (15.6% vs. 11.3%, P = 0.3). While regarding the most concerning form of OHSS, namely moderate and severe OHSS, this study demonstrated superior protective effect of calcium infusion over oral carbergoline and this is significant statistically as regards the moderate OHSS (8.6% vs. 1.7%, p = 0.01) and despite it is not significantly statistically in severe form OHSS, it reduce its relative risk by 75% (one case in CIG vs four cases in OCG). The higher incidence of OHSS in this trial in OCG could be secondary to inclusion of severe high -risk women for OHSS other than included in similar trials as earlier studies found the incidence of OHSS is $20, 33% for mild cases 3-6% for moderate cases and 0.5-5% for severe cases in general IVF/ICSI patients [2, 19, 26] .
Also this trial demonstrated that despite reduction of overall, moderate and severe OHSS incidence with calcium infusion there is no reduction in implantation rate, pregnancy rate and live birth rate. This study results were in agreement with trials utilizing calcium infusion for prevention of OHSS in high-risk women undergoing IVF/ICSI cycles when calcium infusion compared with placebo [9, 13, 16] and when compared with oral carbergoline [18] , but the latter trial didn't found superiority of calcium infusion over oral carbergoline statistically significant (CIG 9/98 (9.2%) be 6 mild, 12 moderate, 1 severe OHSS versus OCG10/104 (15.4%) be 10 mild, 14 moderate, 2 severe). The higher incidence of OHSS is in this study due to higher severe inclusion criteria for risk of OHSS development. Also this could explain the difference in reported incidence of OHSS from the trials comparing calcium infusion with placebo as El-Khayat & Elsadek's trail, where they reported with calcium infusion 7/100(7%) versus 23/100 (23%) in placebo developed OHSS but the mild, moderate, severe was 6 (6%), 1 (1%), 0 (0%) in CIG versus 11 (11%), 8 (8%), 4 (4%) in placebo group as well as this difference is statistically significant in favor of calcium infusion in overall (P = 0.02), moderate (P = 0.017), severe (P = 0.043) OHSS occurence.
Despite that both oral cabergoline and calcium infusion played against the chief player in OHSS, namely VEGF [27] , the calcium infusion attacked earlier steps in OHSS pathogenesis cascade as proposed in earlier studies that higher intracellular and extracellular calcium inhibits cyclic adenosine monophosphate -stimulated rennin secretion which decreases angiotensin II, which in turn reduce VEGF mRNA and protein expression in human granulosalutein cells [28, 29, 30, 31] , While cabergoline antagonizing the VEGF receptor [11, 12] . Additional proof for pathophysiological basis of calcium infusion efficacy in vascular permeability control recently introduced by Kiston et al. in their randomized trial in rat model [32] .
In this study, OHSS was early and late, but the early was the main in both groups, this in agreement with Carizz et al. [33] but in contrast to Naredi and Karnnakaron as the later authors were carried out freezing of all embryos so, late onset OHSS was not evaluated in their study [18] .
The strength of the present study is that it was prospective and a randomized controlled trial. Also, it was powered as well as bias was only limited to reporting type. While the limitations were the unblinded, which couldn't be feasible as introducing placebo against calcium infusion as well as oral cabergoline will make trial very difficult to be conducted. However we suggest the other researchers if possible, perform double-blind, randomized Clinical trial by using saline 0.9% sham infusion as placebo agonist calcium infusion as well as dummy tablets like cabergoline oral tablets, so complete blinding could be introduced and all types of bias could be controlled (double dummy trial). We also, suggested further investigators to concentrate on incidence of moderate and severe OHSS and powder there trials according to this OHSS categories.
Despite the reduced incidence and severity of OHSS after administration of both type of intervention namely oral cabergoline and calcium infusion with the superiority of the later, a few issues about more reduction of OHSS incidence and severity remain. If the time of starting oral cabergoline or calcium infusion or both at time of HCG triggering, further decrease in OHSS incidence and severity could be achieved. So, further future trials could be designed to evaluate the more effective time of administrating oral cabergoline, calcium infusion either at time of OPU or time of HCG triggering, alone or in combination.
Conclusion
The present trial demonstrated that intravenous calcium gluconate infusion of 10%, 10 ml in 200 ml saline 0.9% over 30 min in day of OPU, and day 1, 2, 3 after OPU was more effective than 7 days oral cabergoline intake of 0.5 mg/daily from OPU day in significantly lowering the incidence and severity of OHSS in high risk women for developing OHSS in context of IVF/ICSI cycles without negative effective of both treatment modality on pregnancy outcomes.
